| Title: |
Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia |
| Authors: |
Soegiarto, Gatot; Mahdi, Bagus Aulia; Wulandari, Laksmi; Fahmita, Karin Dhia; Hadmoko, Satrio Tri; Gautama, Hendra Ikhwan; Prasetyaningtyas, Dewi; Prasetyo, Muhammad Edwin; Negoro, Pujo Prawiro; Arafah, Nur; Purnomosari, Dewajani; Tinduh, Damayanti; Husada, Dominicus; Baskoro, Ari; Fetarayani, Deasy; Nurani, Wita Kartika; Oceandy, Delvac |
| Source: |
Soegiarto, G, Mahdi, B A, Wulandari, L, Fahmita, K D, Hadmoko, S T, Gautama, H I, Prasetyaningtyas, D, Prasetyo, M E, Negoro, P P, Arafah, N, Purnomosari, D, Tinduh, D, Husada, D, Baskoro, A, Fetarayani, D, Nurani, W K & Oceandy, D 2023, 'Evaluation of Antibody Response and Adverse Effects following Heterologous COVID-19 Vaccine Booster with mRNA Vaccine among Healthcare Workers in Indonesia', Vaccines, vol. 11, no. 7, 1160. https://doi.org/10.3390/vaccines11071160 |
| Publication Year: |
2023 |
| Collection: |
The University of Manchester: Research Explorer - Publications |
| Subject Terms: |
COVID-19; adverse event; antibody response; booster; comorbidity; healthcare worker; inactivated viral vaccine; mRNA vaccine; vaccine |
| Description: |
Background: The administration of the third (or booster) dose of COVID-19 vaccine is important in maintaining protection against SARS-CoV-2 infection or the severity of the disease. In Indonesia, health care workers (HCWs) are among the first to receive a booster dose of the COVID-19 vaccine. In this study, we evaluated the antibody response and adverse events following heterologous booster vaccine using mRNA-1273 among HCWs that were fully vaccinated with inactivated viral vaccine as the priming doses. Methods: 75 HCWs at Dr. Soetomo General Hospital in Surabaya, Indonesia, participated in this study. The level of antibody against the SARS-CoV-2 receptor binding domain was analyzed at 1, 3, and 5 months following the second priming dose and at 1, 3, and 5 months after the booster dose. Results: We found a significantly higher level of antibody response in subjects receiving a booster dose of the mRNA-1273 vaccine compared to those receiving an inactivated viral vaccine as a booster. Interestingly, participants with hypertension and a history of diabetes mellitus showed a lower antibody response following the booster dose. There was a higher frequency of adverse events following injection with the mRNA-1273 vaccine compared to the inactivated viral vaccine, although the overall adverse events were considered minor. Conclusions: A heterologous booster dose using mRNA vaccine resulted in a high antibody response; however, participants with hypertension and diabetes mellitus displayed a lower antibody response. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
2076-393X |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/37514976; info:eu-repo/semantics/altIdentifier/pissn/2076-393X |
| DOI: |
10.3390/vaccines11071160 |
| Availability: |
https://research.manchester.ac.uk/en/publications/15c63b49-886c-48e8-89b9-a933f7ee22b0; https://doi.org/10.3390/vaccines11071160 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.71F806FD |
| Database: |
BASE |